Genesis Research Group unveils enhanced US market access data analytics
November 21, 2024 |
Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities to inform US market access strategy. Alongside this, Genesis also announces the appointment of Ki Park as Vice President, Market Access Strategy & Analytics.
This latest development further enhances Genesis Research Group’s integrated, dynamic approach to market access by combining the power of real-world data analytics with accelerated insights from the RPR Platform, which connects to 3,500+ stakeholders across 65+ countries. This unique integration of comprehensive stakeholder intelligence, real-world data analytics, and a differentiated engagement model provides life sciences companies with the rigorous and validated evidence required to enable timely strategic decisions with unprecedented confidence.
Ki Park brings with him over 20 years of US market access experience. His expertise in data analytics and market access will play a crucial role in enabling clients to leverage data and market intelligence to optimize access, from pre-launch through loss of exclusivity, by effectively navigating current and future market trends.
Ki Park, Vice President, Market Access Strategy & Analytics, commented: “Genesis Research Group helps its clients to innovate differently, and I am excited to join the business at a pivotal stage as it expands its capabilities and service offerings.
“The integration of real-world data analytics with the capabilities of RPR™ in the areas of contracting strategy, market assessment, patient affordability program optimization and healthcare policy impact will significantly enhance our clients’ ability to navigate the US market landscape, providing them with validated evidence-based insights necessary for success in today’s competitive environment. Alongside our unique proficiency in gaining insights from relevant stakeholders, Genesis has a superior ability to bolster that information with data, demonstrating what is happening in the real world quickly and efficiently.”
The company’s enhanced access and pricing capabilities deliver key insights on:
- Market potential for a potential launch product or new indication by analyzing the patient journey and assessing the barriers launch products might face by leveraging data analytics coupled with stakeholder input.
- Payer perceptions on product positioning and associated rebate levels can be combined with payer segmentation analytics to understand the opportunity to move share by payers’ ability to control product utilization.
- Patient access and avenues to optimize co-pay assistance programs leveraging within therapeutic area patients’ response to out-of-pocket costs and understand stakeholders’ views on the necessity and impact of such programs.
- Impact of IRA on patient access, leveraging real-world data layered with payer perceptions to assess and test potential scenarios.
David W. Miller, Chief Executive Officer of Genesis Research Group, said: “This expanded offering reflects our commitment to providing our US market access clients with rigorous, actionable insights that empower them to make more informed decisions. By integrating analytics capabilities within our existing framework, we are enhancing our ability to support clients at every stage of their market access journey. On behalf of the whole organization, I warmly welcome Ki and look forward to utilizing his wealth of expertise within the US market access and data analytics landscape.”
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
How does Genesis Research Group ‘Innovate differently’?
New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to ‘Innovate differently’ and transform the way they engage…
Envision Analogue – An Introduction
Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive…
World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group
A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies…
Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences
This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs. Regulators and agencies responsible for market…
Genesis Research Group RWD / HTA / regulatory / ECA webinar on 15 Feb: reserve your place!
On 15 February 2024, Carole Longson and Allie Sosinsky of Genesis Research Group, a leading global provider of tech-enabled real-world evidence, market access, and HEOR solutions, will present a webinar…